Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (121-130 of 236) with videos related to

Pageof 24
Sort By:
Nature Communications|February 1, 2020
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cellsJason B Williams, Shuyin Li, Emily F Higgs, et al.
Annals of Surgical Oncology|June 15, 2021
Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare PatientsSaam A Mojtahed, Nicole R Boyer, Saieesh A Rao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2016
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNALeticia Corrales, Seng-Ryong Woo, Jason B Williams, et al.
Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Biopreservation and Biobanking|June 30, 2022
Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics ToolsEmily F Higgs, Blake A Flood, Athalia R Pyzer, et al.
Cancer Cell|January 18, 2014
Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responsesXuanming Yang, Xunmin Zhang, May Lynne Fu, et al.
Cancer Immunology Research|August 17, 2022
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 CytokinesRobin Reschke, Jason W Shapiro, Jovian Yu, et al.
Journal for Immunotherapy of Cancer|February 5, 2015
T cell-NF-κB activation is required for tumor control in vivoSarah E Barnes, Ying Wang, Luqiu Chen, et al.
Journal of Neuroimmunology|March 1, 2006
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapySimona Velicu, Yu Han, Ilya Ulasov, et al.
Cancer Research|March 19, 2009
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentHelena Harlin, Yuru Meng, Amy C Peterson, et al.
Pageof 24

Showing results (121-130 of 236) with videos related to

Sort By:
Pageof 24
Nature Communications|February 1, 2020
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cellsJason B Williams, Shuyin Li, Emily F Higgs, et al.
Annals of Surgical Oncology|June 15, 2021
Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare PatientsSaam A Mojtahed, Nicole R Boyer, Saieesh A Rao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 2, 2016
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNALeticia Corrales, Seng-Ryong Woo, Jason B Williams, et al.
Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Biopreservation and Biobanking|June 30, 2022
Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics ToolsEmily F Higgs, Blake A Flood, Athalia R Pyzer, et al.
Cancer Cell|January 18, 2014
Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responsesXuanming Yang, Xunmin Zhang, May Lynne Fu, et al.
Cancer Immunology Research|August 17, 2022
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 CytokinesRobin Reschke, Jason W Shapiro, Jovian Yu, et al.
Journal for Immunotherapy of Cancer|February 5, 2015
T cell-NF-κB activation is required for tumor control in vivoSarah E Barnes, Ying Wang, Luqiu Chen, et al.
Journal of Neuroimmunology|March 1, 2006
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapySimona Velicu, Yu Han, Ilya Ulasov, et al.
Cancer Research|March 19, 2009
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitmentHelena Harlin, Yuru Meng, Amy C Peterson, et al.
Pageof 24